About Pramlintide
Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety
Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes, and investigated for weight management due to amylin's central role in meal-related satiety signaling. Amylin is co-secreted with insulin from pancreatic beta-cells and slows gastric emptying, suppresses post-meal glucagon release, and activates satiety circuits in the area postrema and nucleus tractus solitarius of the brainstem. Randomized controlled trials demonstrate that subcutaneous pramlintide administration before meals significantly reduces 24-hour caloric intake, meal sizes, and body weight in obese subjects, with effects independent of glycemic control. Pramlintide is an FDA-approved prescription medication (Symlin); its weight management application is off-label in non-diabetic patients, and use requires monitoring for hypoglycemia, particularly when co-administered with insulin. Pramlintide vs cagrilintide: the amylin analogue generation gap Pramlintide (Symlin) is a first-generation amylin analogue with a short half-life requiring injection before each meal — typically 60–120mcg per meal in T1D, or 120mcg per meal in T2D — making three daily injections standard. Cagrilintide, currently in Phase 3 development, is a long-acting amylin analogue designed for once-weekly subcutaneous administration, combining with semaglutide in the CagriSema combination. The practical distinction is significant: pramlintide's thrice-daily injection burden limits adherence, particularly in non-diabetic weight management contexts. Cagrilintide's weekly dosing removes this barrier and enables combination with a weekly GLP-1 agonist in a single injection protocol. Pramlintide for weight management: In adults without diabetes, pramlintide produces modest mean weight reductions of 3–5% over 6-month studies — less than GLP-1 agonists but with a complementary mechanism. Some researchers have combined pramlintide with a GLP-1 agonist (pramlintide + GLP-1) as an early-generation dual amylin/incretin approach, reporting additive weight reductions. CagriSema (cagrilintide + semaglutide) in Phase 3 represents the pharmacologically optimised version of this dual approach, with superior efficacy and weekly dosing. Pramlintide's practical role in new weight management programs has therefore narrowed significantly as cagrilintide and GLP-1/amylin combinations approach approval.
Pramlintide Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- March 16, 2005
- Source
- View FDA source →
FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
3 sources cited · 1 strong · 2 moderate
2 RCTs · 1 Review
Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind, dose-response study
American Journal of Physiology: Endocrinology and Metabolism · 2007
Research in an 8-week dose-response trial found that subcutaneous pramlintide reduced 24-hour caloric intake by 680 to 990 kcal and produced mean body weight reduction of 2.1% compared with a 0.1% gain in placebo-treated obese adults, supporting its role as a satiety-promoting agent.
Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and leptin requirements
Obesity · 2009
Research in a 24-week combination trial found that pramlintide plus metreleptin produced a mean body weight reduction of 12.7% compared with 8.4% for pramlintide alone and 8.2% for metreleptin alone in obese adults, suggesting synergistic satiety effects from dual amylin and leptin receptor engagement.
Pramlintide.
2006
# Summary This study demonstrated that pramlintide is unlikely to pass into breastmilk in clinically significant amounts due to its high molecular weight, short half-life, and peptide structure that would be digested in an infant's gastrointestinal tract. Researchers observed that while theoretical risk to breastfed infants appears minimal, limited clinical data on pramlintide use during breastfeeding suggests careful monitoring of infants for hypoglycemic symptoms may be warranted.
Pramlintide Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Pramlintide — Providers & Availability
Coverage expanding
No verified providers currently list Pramlintide. Get notified when one does, or explore providers carrying similar peptides in the Fat Loss category.
Stay updated on verified Pramlintide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Pramlintide
Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes, and investigated for weight management due to amylin's central role in meal-related satiety signaling. Amylin is co-secreted with insulin from pancreatic beta-cells and slows gastric emptying, suppresses post-meal glucagon release, and activates satiety circuits in the area postrema and nucleus tractus solitarius of the brainstem.
appetite suppression, postprandial glucose control, weight loss, gastric emptying delay.
Research on Pramlintide primarily documents effects related to appetite suppression and postprandial glucose control and weight loss and gastric emptying delay. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Pramlintide include hypoglycemia unawareness, gastroparesis. This is educational information only — consult a qualified healthcare professional before use.
Research in an 8-week dose-response trial found that subcutaneous pramlintide reduced 24-hour caloric intake by 680 to 990 kcal and produced mean body weight reduction of 2.1% compared with a 0.1% gain in placebo-treated obese adults, supporting its role as a satiety-promoting agent.